IMCD N.V. (0QVU)
London Exchange · UK · prices in EUR · close of 19 Oct 2026
Key indicators
| Last close | EUR 104.20 |
|---|---|
| 52-week range | 66.94 – 105.55 |
| Return, 1 month / 3 months | +11.6% / +19.9% |
| Return, 1 year / 3 years | +15.6% / −1.3% |
| Trend | Uptrend |
| RSI (14) | 67 |
| Volatility (1 year) | 35.5% |
| Worst drawdown (1 year) | -26.2% |
| Average daily value traded | 3.23M EUR |
| Dividend yield | 1.7% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
IMCD N.V. is a distributor of specialty chemicals and ingredients, based in Rotterdam in the Netherlands. The company supplies products and technical support to manufacturers in industries including pharmaceuticals, food and nutrition, personal care, coatings and industrial applications. It works as an intermediary between chemical producers and formulators, offering advice on how ingredients are used and combined. Its customers are companies that make finished goods, and it operates through a network of local offices and application laboratories in many countries.
The shares are listed on the London Exchange in UK under the code 0QVU, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
IMCD N.V. (0QVU) trades on the London Exchange in UK. It last closed at EUR 104.20 on 19 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 803 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 15.6% and over the last three months it rose 19.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 86 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 17.8% | ||
| From 52-week high | -0.5% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 19.9% | ||
| 6-month return | 10.0% | ||
| 12-month return, skipping the last month | 3.6% | ||
| Stability (higher is calmer) | 53 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 35.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -26.2% | ||
| Liquidity | 64 · Fair | Moderate trading activity. | |
| Average daily value traded | 3.23M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 49 · Weak | Dividend is small or irregular. | |
| Dividend yield | 1.7% | ||
| Years with dividends | 5 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Income: Dividend is small or irregular.
Returns
| 1 week | +3.9% |
|---|---|
| 1 month | +11.6% |
| 3 months | +19.9% |
| 6 months | +10.0% |
| 1 year | +15.6% |
| 3 years | −1.3% |
| 5 years | −39.0% |
Signals
| 50-day / 200-day average | 97.52 / 88.44 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.18 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 5 May 2026 | EUR 1.8100 |
| 29 Apr 2025 | EUR 2.1500 |
| 16 May 2024 | EUR 2.2400 |
| 28 Apr 2023 | EUR 2.3700 |
| 4 May 2022 | EUR 1.6200 |
| 24 Jun 2021 | EUR 1.0200 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.